Navigation Links
Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
Date:8/19/2007

BASINGSTOKE, England and PHILADELPHIA, August 15 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces that the waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its exclusive license of JUVISTA(R) (human TGF BETA 3) from Renovo Group plc (LSE: RNVO) expired on August 10, 2007. In accordance with its terms, the License Agreement became effective on August 15, 2007.

JUVISTA is a novel biopharmaceutical investigational drug and when injected at the time of surgery has been shown in clinical trials to markedly improve subsequent scar appearance in the skin.

Under the terms of the agreement, Shire has the exclusive right to commercialize JUVISTA worldwide, with the exception of EU member states. Shire's financial obligations under the agreement are geared to JUVISTA's successful development and commercialization. Shire will now pay Renovo US$75 million upfront (expensed during the third quarter as R&D for US GAAP purposes) and in addition, Shire will make an equity investment in Renovo of US$50 million (at a subscription price of GBP2 per share, which represents approximately 6.5% of Renovo's share capital immediately after the issue).

On the FDA's acceptance of filing of JUVISTA's biologics license application, Shire will pay US$25 million and on FDA approval, between US$50 and US$150 million depending on the characteristics of the approved product labelling. Shire will also pay Renovo royalties on sales of JUVISTA and milestone payments of up to US$525 million on the achievement of very significant sales targets.

Notes to Editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestina
'/>"/>

SOURCE Shire PLC

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Im Still Waiting for the Information Age in Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Chairman of Audit committee, TUSTIN, Calif., Nov. 5 ... announced today Mr. Douglas MacLellan has been elected by,its ... Officer and Executive,Chairman effective immediately. Mr. Michael Boswell has ... former role as Chairman of AMDL,s,Audit committee and long-standing ...
... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... & Renshaw 10th Annual Healthcare Conference on,Tuesday, November ... will be held at,the New York Palace Hotel ... about this conference, please visit:, http://www.rodmanandrenshaw.com/conferences?id=19 , ...
... Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC Bulletin Board: ... pumps and associated clinical services,today announced financial results ... ended September 30, 2008., Mr. Steve Watkins, ... a solid 14.5% increase in revenue for the ...
Cached Biology Technology:AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 2AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 3AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Resveratrol, a compound in grapes, displays antioxidant and ... researchers at the UT Health Science Center San Antonio ... beneficial health effects. Resveratrol stimulates the expression of ... store fat, the team found. Adiponectin has a wide ...
... The bacterium which causes acne (Propionibacterium acnes) will be the ... Peter Lambert of Aston University. As well as acne, this ... is often ignored at diagnosis. Why are we not more ... length of stomach upsets and boost the immune system: , ...
... study that relates global energy use to economic growth, ... finds strong correlations between these two measures both among ... the study,s authors to infer that energy use limits ... in energy supply will be required to meet the ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2Probiotics, prebiotics and biofuel-producing bacteria 2Study finds energy limits global economic growth 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: